Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

David L. Paterson, Helmi Sulaiman, Po‐Yu Liu, Mark D. Chatfield, Mesut Yılmaz, Zeti Norfidiyati Salmuna, Mohd Zulfakar Mazlan, Siriluck Anunnatsiri, Rujipas Sirijatuphat, Darunee Chotiprasitsakul, David Chien Lye, Jyoti Somani, Shirin Kalimuddin, Abdullah Tarık Aslan, Visanu Thamlikitkul, Yi‐Tzu Lee, Ya‐Sung Yang, Yi-Tsung Lin, Wan Nurliyana Wan Ramli, Chien-Hao Tseng, Sophia Archuleta, Yvonne Fu Zi Chan, Brian M. Forde, Hugh Wright, Adam G. Stewart, Kay A. Ramsay, Weiping Ling, Vicki Rossi, Tiffany Harris‐Brown, Patrick N. A. Harris